Preveceutical Medical Inc. announced appointment of C. Evan Ballantyne to PreveCeutical's Board of – Directors, effective February 17, 2023. Mr. Ballantyne has extensive executive leadership experience and has spent the last 20 years as a public and private company Chief Financial Officer in the healthcare industry. He was most recently the CFO of OncXerna Therapeutics Inc., where he worked to advance partnering opportunities for the company's biomarker program.

Prior to OncXerna, Ballantyne was CFO at Orchestra BioMed Inc., where he assisted with the closing of two equity financing rounds with proceeds of $57 million. At Orchestra, he also helped close a global partnership deal valued at more than $200 million. Before Orchestra, Mr. Ballantyne was the CFO of Cerecin Inc., an Alzheimer's disease-focused company backed by Nestl Health Science.

Ballantyne was Executive Vice President and CFO of Clinical Data Inc., a biopharmaceutical company acquired by Forest Labs (acquired by Allergan) for $1.6 billion. He also served as the CFO of the microbiome-focused company Synthetic Biologics Inc., and as well as the CFO of the immuno-oncology company Agenus Inc., where he helped monetize a GlaxoSmithKline royalty stream for gross proceeds of $115 million. In addition to these roles, Mr. Ballantyne was the CFO and Chief Operating Officer of ACNielsen.

Mr. Ballantyne holds a B.A.in History and Political Science from the University of Western Ontario and a post-graduate degree in Business Administration from the University of Windsor.